Funxional Therapeutics (FXT) Ltd was founded in August 2005 to exploit a new paradigm in drug discovery based around high throughput functional assays.  The lead compound, BN83470, is an oral, small molecule anti-inflammatory agent with a unique mechanism of action.

www.funxionaltherapeutics.com

FingerPrint Diagnostics (FPD) Ltd was spun-out of TCP Innovations in 2002.  Its unique technology platform allows rapid, non-invasive diagnosis of a range of diseases including heart disease based on a low cost method of obtaining biological fingerprints.  FPD aims to launch its lead product, the CADprint test, some time in 2007.

www.fingerprintdiagnostics.com

Prolinex uses metabolic profiling to develop high-tech food supplements for direct-to-consumer sales.  Lead products (which are all novel neutraceuticals developed in-house) in osteoporosis, heart disease and arthritis are under development, with the first launch scheduled for late 2006.  Prolinex aims to be the first company to apply the same rigorous standards as pharmaceutical development to the creation of food supplement products supported by real scientific evidence.

www.prolinex.com

Metabometrix Ltd is a spin-out company built on the skills of the world's pre-eminent metabonomics research team at Imperial College, London, and experienced scientists from the UK and US pharmaceutical industries.  Metabonomics (or metabolic profiling) has been developed over 15 years by a world-leading team directed by Professor Jeremy Nicholson, the Chief Scientist of Metabometrix. The group's portfolio of intellectual and technical advances is unique, and underpins a substantial lead in the field.  The company has a proprietary platform of metabonomics technologies for generating, classifying and interpreting metabolic information from biological fluids and tissues.

www.metabometrix.com